Tim G. Eisen

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 86 publications

Therapeutic challenges of a renal collision tumour comprising clear cell renal cell carcinoma and metastatic breast carcinoma: a case report.

Therapeutic challenges of a renal collision tumour comprising clear cell renal cell carcinoma and metastatic breast carcinoma: a case report.

Journal: BJC reports

Published: February 03, 2026

Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor-Resistant Patients in Clear Cell Renal Cell Carcinoma.

Multiplexed P21/MCM-2 Detection Predicts Relapse and May Identify Tyrosine Kinase Inhibitor-Resistant Patients in Clear Cell Renal Cell Carcinoma.

Journal: Cancer research communications

Published: December 19, 2025

Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.

Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.

Journal: Abdominal radiology (New York)

Published: August 20, 2025

Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials.

Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials.

Journal: European urology open science

Published: July 01, 2025

Establishing the China-UK Cancer Prevention and Control Alliance.

Establishing the China-UK Cancer Prevention and Control Alliance.

Journal: The Lancet. Oncology

Published: May 08, 2025

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.

Journal: Health technology assessment (Winchester, England)

Published: September 09, 2024

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma.

Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma.

Journal: Neoplasia (New York, N.Y.)

Published: July 23, 2024

Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.

Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report.

Journal: Contemporary clinical trials communications

Published: October 16, 2023

Reply to U. Capitanio et al.

Reply to U. Capitanio et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 27, 2022

Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib.

Journal: Cancers

Published: April 11, 2022

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).

Journal: British journal of cancer

Published: March 14, 2022

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 25, 2022

Showing 1-12 of 86

Last Updated: 09/26/2026